Home |Hyderabad |Hyderabad Doctor Secures Affordable Rare Disease Drug For Seven Children With Ahds
Hyderabad doctor secures affordable rare disease drug for seven children with AHDS
A Hyderabad-based paediatrician, Dr Sivaranjani Santosh, has facilitated access to affordable Tiratricol treatment for seven children suffering from the rare genetic disorder Allan-Herndon-Dudley syndrome (AHDS). The initiative, supported by Access to Medicines India and the Pharmaceutical Accountability Foundation, has significantly reduced treatment costs for the patients’ families.
Hyderabad-based paediatrician Dr Sivaranjani Santosh
Hyderabad: In a relief for families battling rare genetic disorders, city-based paediatrician Dr Sivaranjani Santosh, alongside Access to Medicines India, is set to hand over life-saving medication to seven children suffering from Allan-Herndon-Dudley syndrome (AHDS) on November 30.
The medicine, Tiratricol, crucial for managing the rare MCT8 deficiency affecting thyroid hormone transport into brain cells, has been custom-compounded by a Netherlands-based pharmacy through the Pharmaceutical Accountability Foundation (PAF).
While commercial variants of the medicine cost an astronomical Rs 4.68 crore to Rs 9 crore annually, the compassionate batch for the children, sourced by a senior Hyderabad-based paediatrician, costs roughly Rs 2.5 lakh per child per year.
The breakthrough followed an extensive social media advocacy campaign launched by Dr Sivaranjani after her young patient, Arav, struggled to sustain monthly import costs of Rs 12 lakh to Rs 13 lakh from Germany.
The appeal caught the attention of PAF, paving the way for cost-effective pharmaceutical compounding. Beneficiaries include children under Dr Sivaranjani’s care and five patients identified at Christian Medical College (CMC), Vellore.
While individual import permits have been secured for a year, healthcare advocates said that relying on foreign imports is unsustainable. Dr Sivaranjani plans to urge the Union government to encourage domestic production, aiming to make treatment permanently affordable for all children nationwide.